584 lines
36 KiB
HTML
584 lines
36 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN" data-theme="night">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>中药概念深度行研报告</title>
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.11.1/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<style>
|
||
@import url('https://fonts.googleapis.com/css2?family=Noto+Sans+SC:wght@300;400;500;700&display=swap');
|
||
|
||
body {
|
||
font-family: 'Noto Sans SC', sans-serif;
|
||
background-color: #0D0B14;
|
||
color: #E0E0E0;
|
||
overflow-x: hidden;
|
||
position: relative;
|
||
}
|
||
|
||
body::before {
|
||
content: '';
|
||
position: fixed;
|
||
top: -20%;
|
||
left: -20%;
|
||
width: 80vw;
|
||
height: 80vh;
|
||
background: radial-gradient(circle, rgba(147, 51, 234, 0.15) 0%, rgba(13, 11, 20, 0) 60%);
|
||
filter: blur(80px);
|
||
z-index: -1;
|
||
animation: move-glow-1 20s infinite alternate;
|
||
}
|
||
|
||
body::after {
|
||
content: '';
|
||
position: fixed;
|
||
bottom: -20%;
|
||
right: -20%;
|
||
width: 80vw;
|
||
height: 80vh;
|
||
background: radial-gradient(circle, rgba(59, 130, 246, 0.15) 0%, rgba(13, 11, 20, 0) 60%);
|
||
filter: blur(80px);
|
||
z-index: -1;
|
||
animation: move-glow-2 25s infinite alternate;
|
||
}
|
||
|
||
@keyframes move-glow-1 {
|
||
from { transform: translate(-10%, -10%) rotate(0deg); }
|
||
to { transform: translate(10%, 10%) rotate(45deg); }
|
||
}
|
||
|
||
@keyframes move-glow-2 {
|
||
from { transform: translate(10%, 10%) rotate(0deg); }
|
||
to { transform: translate(-10%, -10%) rotate(-45deg); }
|
||
}
|
||
|
||
.glass-card {
|
||
background: rgba(23, 23, 35, 0.5);
|
||
backdrop-filter: blur(20px);
|
||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||
border-radius: 1.5rem; /* 24px */
|
||
transition: all 0.3s ease;
|
||
}
|
||
|
||
.glass-card:hover {
|
||
border-color: rgba(147, 51, 234, 0.5);
|
||
box-shadow: 0 0 30px rgba(147, 51, 234, 0.2);
|
||
}
|
||
|
||
.bento-grid {
|
||
display: grid;
|
||
gap: 1.5rem;
|
||
grid-template-columns: repeat(12, 1fr);
|
||
}
|
||
|
||
.bento-item {
|
||
grid-column: span 12;
|
||
}
|
||
@media (min-width: 768px) {
|
||
.bento-item-col-6 { grid-column: span 6; }
|
||
.bento-item-col-4 { grid-column: span 4; }
|
||
.bento-item-col-8 { grid-column: span 8; }
|
||
.bento-item-col-12 { grid-column: span 12; }
|
||
}
|
||
@media (min-width: 1024px) {
|
||
.bento-item-lg-col-3 { grid-column: span 3; }
|
||
.bento-item-lg-col-4 { grid-column: span 4; }
|
||
.bento-item-lg-col-5 { grid-column: span 5; }
|
||
.bento-item-lg-col-6 { grid-column: span 6; }
|
||
.bento-item-lg-col-7 { grid-column: span 7; }
|
||
.bento-item-lg-col-8 { grid-column: span 8; }
|
||
.bento-item-lg-col-12 { grid-column: span 12; }
|
||
}
|
||
|
||
.text-glow {
|
||
text-shadow: 0 0 8px rgba(192, 132, 252, 0.8);
|
||
}
|
||
|
||
.table thead th {
|
||
background-color: rgba(147, 51, 234, 0.2);
|
||
color: #E0E0E0;
|
||
border-bottom: 1px solid rgba(255, 255, 255, 0.2);
|
||
}
|
||
|
||
.table tbody tr {
|
||
background-color: transparent;
|
||
transition: background-color 0.3s ease;
|
||
}
|
||
|
||
.table-zebra tbody tr:nth-child(odd) {
|
||
background-color: rgba(255, 255, 255, 0.03);
|
||
}
|
||
|
||
.table tbody tr:hover {
|
||
background-color: rgba(59, 130, 246, 0.2);
|
||
}
|
||
|
||
.accordion-item {
|
||
background: rgba(23, 23, 35, 0.7);
|
||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||
border-radius: 1rem;
|
||
margin-bottom: 1rem;
|
||
}
|
||
.accordion-title {
|
||
color: #E0E0E0;
|
||
font-weight: 500;
|
||
}
|
||
.accordion-content {
|
||
color: #b0b0b0;
|
||
}
|
||
|
||
</style>
|
||
</head>
|
||
<body class="min-h-screen p-4 sm:p-6 lg:p-8">
|
||
<div class="max-w-7xl mx-auto space-y-8">
|
||
<!-- Header -->
|
||
<header class="text-center py-8">
|
||
<h1 class="text-4xl md:text-6xl font-bold bg-clip-text text-transparent bg-gradient-to-r from-purple-400 to-blue-400 text-glow">
|
||
中药概念 深度行研报告
|
||
</h1>
|
||
<p class="mt-4 text-sm text-gray-400">
|
||
北京价值前沿科技有限公司 AI投研agent：“价小前投研” 呈现
|
||
</p>
|
||
<p class="text-xs text-gray-500 mt-1">本报告为AI合成数据，投资需谨慎。</p>
|
||
</header>
|
||
|
||
<!-- Core Insight -->
|
||
<section id="insight" class="glass-card p-6 md:p-8">
|
||
<h2 class="text-2xl md:text-3xl font-bold mb-6 text-purple-300 border-l-4 border-purple-400 pl-4">核心洞察：从周期底部到结构性升级的价值重塑</h2>
|
||
|
||
<div class="space-y-6 text-gray-300">
|
||
<div class="p-4 border border-dashed border-gray-600 rounded-xl">
|
||
<p class="font-semibold text-lg text-white">核心观点摘要</p>
|
||
<p>中药概念正处在一个由<strong class="text-purple-300">政策强力驱动的、从周期性底部向结构性升级转型的关键拐点</strong>。其核心驱动力源于国家层面为解决中药质量、创新和产业现代化问题而推出的系统性顶层设计。未来，行业的增长潜力将不再是普涨，而是分化为<strong class="text-blue-300">品牌消费、科技创新和国企改革</strong>三大主线，具备全产业链控制力、研发实力和品牌护城河的企业将获得长期价值重估。</p>
|
||
</div>
|
||
|
||
<div>
|
||
<h3 class="text-xl font-semibold mb-3 text-white">概念事件与催化时间轴</h3>
|
||
<ul class="list-disc list-inside space-y-2 pl-2 text-sm">
|
||
<li><strong class="text-gray-100">背景 (2023-2024年中):</strong> 经历需求与库存的周期性波动，板块表现跑输医药整体，中药材价格高企压制毛利率，市场处于<strong class="text-red-400">估值与公募基金配置双低</strong>状态。</li>
|
||
<li><strong class="text-gray-100">2024年8月-12月:</strong> 产业整合信号出现（华润三九收购天士力股权，昆药、同仁堂等频繁收购）。</li>
|
||
<li><strong class="text-gray-100">2025年1月3日:</strong> 国务院发文，明确提出<strong class="text-green-400">完善中药特色审评体系</strong>，支持新药转化。</li>
|
||
<li><strong class="text-gray-100">2025年3月20日:</strong> 国务院再发文，从资源保护到创新研发提出8方面21项重点内容，是顶层设计的重大利好。</li>
|
||
<li><strong class="text-gray-100">2025年9月8日:</strong> 国家药监局公布《中药生产监督管理专门规定》，旨在健全全生命周期监管，推动产业升级和“新质生产力”发展。</li>
|
||
</ul>
|
||
</div>
|
||
|
||
<div>
|
||
<h3 class="text-xl font-semibold mb-3 text-white">预期差分析：宏大叙事与短期阵痛的背离</h3>
|
||
<div class="grid md:grid-cols-3 gap-4 text-sm">
|
||
<div class="p-4 bg-black/20 rounded-lg">
|
||
<p class="font-bold text-purple-300">政策利好 vs. 集采压力</p>
|
||
<p>市场普遍认知行业前景光明，但忽略了集采带来的短期“阵痛”。路演数据显示，中药配方颗粒集采降幅达<strong class="text-red-400">45%-70%</strong>，中成药集采平均降幅从42%扩大至<strong class="text-red-400">68%</strong>，直接冲击企业盈利能力。</p>
|
||
</div>
|
||
<div class="p-4 bg-black/20 rounded-lg">
|
||
<p class="font-bold text-blue-300">需求复苏 vs. 库存周期</p>
|
||
<p>市场看重老龄化带来的长期需求，但低估了渠道去库存和消化高价原材料库存对<strong class="text-yellow-400">2025年上半年业绩</strong>的拖累。短期业绩受周期性影响显著。</p>
|
||
</div>
|
||
<div class="p-4 bg-black/20 rounded-lg">
|
||
<p class="font-bold text-green-300">全面创新 vs. 研发短板</p>
|
||
<p>市场认知中药企业纷纷创新，但研报数据显示，中药临床试验仅占总量的<strong class="text-yellow-400">3.3%</strong>，启动效率（15.8%）远低于化药（~60%），整体创新能力和效率仍是短板。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div>
|
||
<h3 class="text-xl font-semibold mb-3 text-white">关键催化剂与未来发展路径</h3>
|
||
<div class="flex flex-col md:flex-row gap-4">
|
||
<div class="flex-1 p-4 bg-black/20 rounded-lg">
|
||
<p class="font-bold text-lg mb-2">近期催化剂 (未来3-6个月)</p>
|
||
<ul class="list-decimal list-inside space-y-1 text-sm">
|
||
<li><strong>基药目录调整落地：</strong>将直接驱动相关品种在基层医疗机构放量。</li>
|
||
<li><strong>第四批中成药集采规则明确：</strong>“优质优价”细则与独家品种是否纳入是关键。</li>
|
||
<li><strong>国企改革具体方案出台：</strong>股权激励、资产注入等将直接刺激市场情绪。</li>
|
||
</ul>
|
||
</div>
|
||
<div class="flex-1 p-4 bg-black/20 rounded-lg">
|
||
<p class="font-bold text-lg mb-2">长期发展路径</p>
|
||
<ul class="list-decimal list-inside space-y-1 text-sm">
|
||
<li><strong>第一阶段 (当前-2026):</strong> 政策消化与格局重塑期，行业加速分化。</li>
|
||
<li><strong>第二阶段 (2026-2028):</strong> 创新成果初步兑现期，增长动力转向创新品种。</li>
|
||
<li><strong>第三阶段 (2028以后):</strong> 现代化与国际化发展期，与AI等科技结合，探索全球价值重估。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Industry Deep Dive -->
|
||
<section id="deep-dive" class="bento-grid">
|
||
<div class="bento-item bento-item-col-12 bento-item-lg-col-7 glass-card p-6">
|
||
<h3 class="text-xl font-bold mb-4 text-purple-300">国家政策图景：顶层设计驱动产业变革</h3>
|
||
<div class="space-y-3 text-sm text-gray-300">
|
||
<p><strong>《关于全面深化药品医疗器械监管改革...意见》 (2025-01-03):</strong> 核心是完善中药特色审评证据体系，支持名老中医方、医疗机构制剂向新药转化。</p>
|
||
<p><strong>《关于提升中药质量促进...高质量发展的意见》 (2025-03-20):</strong> 从资源保护、产业升级、品牌战略到创新药研发提出8方面21项重点内容，是纲领性文件。</p>
|
||
<p><strong>《中药生产监督管理专门规定》 (2025-09-08):</strong> 旨在健全符合中药特点的全生命周期监管体系，促进产业升级和“新质生产力”发展。</p>
|
||
<p><strong>医保支付端优化:</strong> 路演信息显示，中医机构暂不实行DRG、保留25%的中药配方颗粒加成，并解除部分OTC和中药注射剂报销限制，提升市场空间。</p>
|
||
</div>
|
||
</div>
|
||
<div class="bento-item bento-item-col-12 bento-item-lg-col-5 glass-card p-6">
|
||
<h3 class="text-xl font-bold mb-4 text-blue-300">行业挑战与风险</h3>
|
||
<div class="space-y-3 text-sm text-gray-300">
|
||
<p><strong>集采降价超预期:</strong> 行业最大不确定性。配方颗粒降幅<strong class="text-red-400">45%-70%</strong>，中成药平均降幅达<strong class="text-red-400">68%</strong>，严重侵蚀企业利润。</p>
|
||
<p><strong>成本压力:</strong> 上游中药材价格周期性波动，对中游企业毛利率构成持续威胁。</p>
|
||
<p><strong>专利保护风险:</strong> 研报显示，部分中药专利（如三七三醇皂苷）被宣告“全部无效”，创新成果面临被挑战风险。</p>
|
||
<p><strong>现代化瓶颈:</strong> 临床试验效率低下，建立基于现代科学的药效评价体系仍是核心挑战。</p>
|
||
</div>
|
||
</div>
|
||
<div class="bento-item bento-item-col-12 bento-item-lg-col-8 glass-card p-6">
|
||
<h3 class="text-xl font-bold mb-4 text-green-300">行业财务与市场数据一览</h3>
|
||
<div id="industry-chart" class="w-full h-80"></div>
|
||
</div>
|
||
<div class="bento-item bento-item-col-12 bento-item-lg-col-4 glass-card p-6 flex flex-col justify-between">
|
||
<div>
|
||
<h3 class="text-xl font-bold mb-4 text-yellow-300">研发与创新</h3>
|
||
<p class="text-sm text-gray-300 mb-4">研报数据显示，中药研发虽受政策鼓励，但基础仍薄弱，效率有待提升。</p>
|
||
</div>
|
||
<div class="space-y-4">
|
||
<div class="text-center">
|
||
<p class="text-4xl font-bold text-yellow-300">3.3%</p>
|
||
<p class="text-sm text-gray-400">2023年中药临床试验占新药试验总量</p>
|
||
</div>
|
||
<div class="text-center">
|
||
<p class="text-4xl font-bold text-yellow-300">15.8%</p>
|
||
<p class="text-sm text-gray-400">6个月内启动招募比例 (远低于化药的56.2%)</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Rise/Fall Analysis -->
|
||
<section id="rise-analysis">
|
||
<h2 class="text-2xl md:text-3xl font-bold mb-6 text-center text-purple-300">个股异动深度解析</h2>
|
||
<div class="space-y-4" x-data="{ active: 1 }">
|
||
<div class="accordion-item" x-data="{ open: false }">
|
||
<div @click="open = !open" class="flex justify-between items-center p-4 cursor-pointer">
|
||
<h3 class="accordion-title text-lg">亚宝药业 (600351) <span class="text-green-400 ml-2">+6.00%</span></h3>
|
||
<span x-show="!open" class="text-2xl text-purple-400">+</span>
|
||
<span x-show="open" class="text-2xl text-purple-400">-</span>
|
||
</div>
|
||
<div x-show="open" x-collapse class="accordion-content p-4 pt-0">
|
||
<p><strong>核心驱动:</strong> 中药板块整体走强 + 公司股份回购计划积极影响。</p>
|
||
<ul class="list-disc list-inside text-sm mt-2 space-y-1">
|
||
<li><strong>板块效应:</strong> 8月1日中药板块逆势拉升，天目药业、华森制药涨停，板块性行情带动个股。</li>
|
||
<li><strong>公司回购:</strong> 发布股份回购进展，拟以0.5-1亿元回购股份并注销，提振投资者信心，为股价提供支撑。</li>
|
||
<li><strong>资金流向:</strong> 市场资金轮动至估值相对较低的中药板块，叠加机构研报看好创新中药，改善市场预期。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
<div class="accordion-item" x-data="{ open: false }">
|
||
<div @click="open = !open" class="flex justify-between items-center p-4 cursor-pointer">
|
||
<h3 class="accordion-title text-lg">启迪药业 (000590) <span class="text-green-400 ml-2">+9.99%</span></h3>
|
||
<span x-show="!open" class="text-2xl text-purple-400">+</span>
|
||
<span x-show="open" class="text-2xl text-purple-400">-</span>
|
||
</div>
|
||
<div x-show="open" x-collapse class="accordion-content p-4 pt-0">
|
||
<p><strong>核心驱动:</strong> 双重政策红利在12小时内集中释放。</p>
|
||
<ul class="list-disc list-inside text-sm mt-2 space-y-1">
|
||
<li><strong>品种保护续保:</strong> 核心产品“古汉养生精”获7年中药保护续保，锁定未来现金流。该品种占收入42%，毛利率高达78%。</li>
|
||
<li><strong>配方颗粒挂网:</strong> 新增300个配方颗粒品规一次性在湖南省挂网，且挂网价高于市场均价，打开增量市场。</li>
|
||
<li><strong>资金反应:</strong> 信息真空期极短，机构席位净买入1.2亿元，以涨停价对公司价值进行重定价。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
<div class="accordion-item" x-data="{ open: false }">
|
||
<div @click="open = !open" class="flex justify-between items-center p-4 cursor-pointer">
|
||
<h3 class="accordion-title text-lg">益佰制药 (600594) <span class="text-green-400 ml-2">+10.07%</span></h3>
|
||
<span x-show="!open" class="text-2xl text-purple-400">+</span>
|
||
<span x-show="open" class="text-2xl text-purple-400">-</span>
|
||
</div>
|
||
<div x-show="open" x-collapse class="accordion-content p-4 pt-0">
|
||
<p><strong>核心驱动:</strong> 业务聚焦 + 业绩改善 + 治理完善。</p>
|
||
<ul class="list-disc list-inside text-sm mt-2 space-y-1">
|
||
<li><strong>全资控股:</strong> 拟收购子公司剩余股权，实现对核心业务“中药配方颗粒”的100%控股，聚焦主业。</li>
|
||
<li><strong>业绩改善:</strong> 2024上半年亏损大幅收窄约81.2%，经营状况向好。</li>
|
||
<li><strong>治理完善:</strong> 修订19项公司治理制度，提升透明度和规范性，增强投资者信心。</li>
|
||
<li><strong>资金信号:</strong> 融资净买入创近一年新高，表明资金看好公司未来发展。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Stock List -->
|
||
<section id="stock-list">
|
||
<h2 class="text-2xl md:text-3xl font-bold mb-6 text-center text-blue-300">核心产业链公司图谱</h2>
|
||
|
||
<!-- 中药种植 -->
|
||
<div class="mb-8">
|
||
<h3 class="text-xl font-semibold mb-4 text-green-300">上游：中药种植</h3>
|
||
<div class="overflow-x-auto glass-card p-2">
|
||
<table class="table table-zebra w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th>核心逻辑/业务</th>
|
||
<th>其他标签</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr><td>振东制药</td><td><a href="https://valuefrontier.cn/company?scode=300158" target="_blank" class="link link-hover text-blue-400">300158</a></td><td>82万亩道地药材基地，种植连翘、酸枣仁、柴胡等</td><td>中药种植</td></tr>
|
||
<tr><td>奇正藏药</td><td><a href="https://valuefrontier.cn/company?scode=002287" target="_blank" class="link link-hover text-blue-400">002287</a></td><td>拥有以野生抚育为主的各类基地总面积达到50余万亩</td><td>中药种植, 民族中药</td></tr>
|
||
<tr><td>太极集团</td><td><a href="https://valuefrontier.cn/company?scode=600129" target="_blank" class="link link-hover text-blue-400">600129</a></td><td>中药材规范化基地在地面积达25万亩，半夏、金荞麦等产量全国首位</td><td>中药种植, 中药OTC</td></tr>
|
||
<tr><td>贵州百灵</td><td><a href="https://valuefrontier.cn/company?scode=002424" target="_blank" class="link link-hover text-blue-400">002424</a></td><td>合作建设中药材种植基地20余万亩</td><td>中药种植</td></tr>
|
||
<tr><td>昆药集团</td><td><a href="https://valuefrontier.cn/company?scode=600422" target="_blank" class="link link-hover text-blue-400">600422</a></td><td>道地药材标准化种植基地10.8万亩，青蒿种植2万亩</td><td>中药种植, 百年/中华老字号, 中药注射剂</td></tr>
|
||
<tr><td>华润三九</td><td><a href="https://valuefrontier.cn/company?scode=000999" target="_blank" class="link link-hover text-blue-400">000999</a></td><td>林下种植中药材面积达8.8万亩。核心产品：999感冒灵、999皮炎平</td><td>中药种植, 驰名药品, 处方中药</td></tr>
|
||
<tr><td>云南白药</td><td><a href="https://valuefrontier.cn/company?scode=000538" target="_blank" class="link link-hover text-blue-400">000538</a></td><td>GAP品种对应基地面积4593亩，入选道地药材品牌</td><td>中药种植, 中药饮片, 百年/中华老字号</td></tr>
|
||
<tr><td>天士力</td><td><a href="https://valuefrontier.cn/company?scode=600535" target="_blank" class="link link-hover text-blue-400">600535</a></td><td>拥有丹参、三七种植基地。在研33款1类创新药</td><td>中药种植, 中药创新药, 处方中药</td></tr>
|
||
<tr><td>同仁堂</td><td><a href="https://valuefrontier.cn/company?scode=600085" target="_blank" class="link link-hover text-blue-400">600085</a></td><td>自有药材种植基地，种植人参、山茱萸等</td><td>中药种植, 百年/中华老字号</td></tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 中药创新药 -->
|
||
<div class="mb-8">
|
||
<h3 class="text-xl font-semibold mb-4 text-purple-300">中游：中药创新药</h3>
|
||
<div class="overflow-x-auto glass-card p-2">
|
||
<table class="table table-zebra w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th>核心逻辑/业务</th>
|
||
<th>其他标签</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr><td>佐力药业</td><td><a href="https://valuefrontier.cn/company?scode=300181" target="_blank" class="link link-hover text-blue-400">300181</a></td><td>乌灵菌粉是国家中药一类新药，开发独家乌灵系列创新药物</td><td>中药创新药, 中药材</td></tr>
|
||
<tr><td>康缘药业</td><td><a href="https://valuefrontier.cn/company?scode=600557" target="_blank" class="link link-hover text-blue-400">600557</a></td><td>治疗肺癌领域中药1.1类创新药龙七胶囊，目前在申报上市阶段</td><td>中药创新药</td></tr>
|
||
<tr><td>以岭药业</td><td><a href="https://valuefrontier.cn/company?scode=002603" target="_blank" class="link link-hover text-blue-400">002603</a></td><td>芪防鼻通片是澳门批准的第一个中成药创新药。核心产品：连花清瘟</td><td>中药创新药, 驰名药品</td></tr>
|
||
<tr><td>新天药业</td><td><a href="https://valuefrontier.cn/company?scode=002873" target="_blank" class="link link-hover text-blue-400">002873</a></td><td>两个在研1.1类创新药，用于急性缺血性卒中、慢性冠脉综合征</td><td>中药创新药, 中药饮片, 处方中药</td></tr>
|
||
<tr><td>珍宝岛</td><td><a href="https://valuefrontier.cn/company?scode=603567" target="_blank" class="link link-hover text-blue-400">603567</a></td><td>在研1.1类中药创新药用于胃食管反流病，正在二期临床</td><td>中药创新药, 中药注射剂</td></tr>
|
||
<tr><td>维康药业</td><td><a href="https://valuefrontier.cn/company?scode=300878" target="_blank" class="link link-hover text-blue-400">300878</a></td><td>在研1.1类中药创新药参丹通脑滴丸、黄甲软肝颗粒</td><td>中药创新药, 中药饮片, 处方中药</td></tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 百年/中华老字号 -->
|
||
<div class="mb-8">
|
||
<h3 class="text-xl font-semibold mb-4 text-yellow-300">中游：百年/中华老字号</h3>
|
||
<div class="overflow-x-auto glass-card p-2">
|
||
<table class="table table-zebra w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th>核心逻辑/业务</th>
|
||
<th>其他标签</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr><td>片仔癀</td><td><a href="https://valuefrontier.cn/company?scode=600436" target="_blank" class="link link-hover text-blue-400">600436</a></td><td>“2024年中华老字号品牌榜”第2位</td><td>百年/中华老字号</td></tr>
|
||
<tr><td>广誉远</td><td><a href="https://valuefrontier.cn/company?scode=600771" target="_blank" class="link link-hover text-blue-400">600771</a></td><td>百年老字号、中华老字号，持有104个国药准字批文</td><td>百年/中华老字号</td></tr>
|
||
<tr><td>九芝堂</td><td><a href="https://valuefrontier.cn/company?scode=000989" target="_blank" class="link link-hover text-blue-400">000989</a></td><td>百年老字号、中华老字号，拥有309个药品批文</td><td>百年/中华老字号</td></tr>
|
||
<tr><td>达仁堂</td><td><a href="https://valuefrontier.cn/company?scode=600329" target="_blank" class="link link-hover text-blue-400">600329</a></td><td>拥有达仁堂、隆顺榕、乐仁堂和京万红等中华老字号品牌</td><td>百年/中华老字号</td></tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 驰名药品 (品牌OTC) -->
|
||
<div class="mb-8">
|
||
<h3 class="text-xl font-semibold mb-4 text-blue-300">中游：驰名药品 (品牌OTC)</h3>
|
||
<div class="overflow-x-auto glass-card p-2">
|
||
<table class="table table-zebra w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th>核心逻辑/业务</th>
|
||
<th>其他标签</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr><td>江中药业</td><td><a href="https://valuefrontier.cn/company?scode=600750" target="_blank" class="link link-hover text-blue-400">600750</a></td><td>江中牌健胃消食片连续21年获非处方药消化类第一名</td><td>驰名药品, 中药OTC</td></tr>
|
||
<tr><td>济川药业</td><td><a href="https://valuefrontier.cn/company?scode=600566" target="_blank" class="link link-hover text-blue-400">600566</a></td><td>核心产品蒲地蓝消炎口服液（独家剂型）、小儿豉翘清热颗粒</td><td>驰名药品, 处方中药</td></tr>
|
||
<tr><td>葵花药业</td><td><a href="https://valuefrontier.cn/company?scode=002737" target="_blank" class="link link-hover text-blue-400">002737</a></td><td>核心产品：小儿肺热咳喘颗粒、小儿柴桂退热颗粒</td><td>驰名药品, 中药OTC</td></tr>
|
||
<tr><td>健民集团</td><td><a href="https://valuefrontier.cn/company?scode=600976" target="_blank" class="link link-hover text-blue-400">600976</a></td><td>第一大单品龙牡壮骨颗粒，独家品种，儿科消化类第一</td><td>驰名药品</td></tr>
|
||
<tr><td>桂林三金</td><td><a href="https://valuefrontier.cn/company?scode=002275" target="_blank" class="link link-hover text-blue-400">002275</a></td><td>核心产品：三金西瓜霜系列</td><td>驰名药品, 中药OTC</td></tr>
|
||
<tr><td>贵州三力</td><td><a href="https://valuefrontier.cn/company?scode=603439" target="_blank" class="link link-hover text-blue-400">603439</a></td><td>核心产品：开喉剑喷雾剂（儿童型）</td><td>驰名药品, 中药材</td></tr>
|
||
<tr><td>红日药业</td><td><a href="https://valuefrontier.cn/company?scode=300026" target="_blank" class="link link-hover text-blue-400">300026</a></td><td>2024年中药配方颗粒及饮片营收26.69亿元。核心产品：血必净注射液</td><td>驰名药品, 中药饮片, 中药注射剂</td></tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- 其他特色 -->
|
||
<div class="mb-8">
|
||
<h3 class="text-xl font-semibold mb-4 text-gray-400">其他特色企业</h3>
|
||
<div class="overflow-x-auto glass-card p-2">
|
||
<table class="table table-zebra w-full">
|
||
<thead>
|
||
<tr>
|
||
<th>股票名称</th>
|
||
<th>股票代码</th>
|
||
<th>核心逻辑/业务</th>
|
||
<th>其他标签</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr><td>佛慈制药</td><td><a href="https://valuefrontier.cn/company?scode=002644" target="_blank" class="link link-hover text-blue-400">002644</a></td><td>投资开设“慈茶馆”，开发药食同源养生茶饮。拟上调产品出厂价9%</td><td>中药饮品, 中药种植, 中药材</td></tr>
|
||
<tr><td>天目药业</td><td><a href="https://valuefrontier.cn/company?scode=600671" target="_blank" class="link link-hover text-blue-400">600671</a></td><td>拥有道地中药饮片1000余种，提供代客煎药等服务。产品“天目山”牌白花蛇草水</td><td>中药饮品, 中药饮片</td></tr>
|
||
<tr><td>奇正藏药</td><td><a href="https://valuefrontier.cn/company?scode=002287" target="_blank" class="link link-hover text-blue-400">002287</a></td><td>国内藏药龙头企业，拥有50余万亩药材基地</td><td>民族中药, 中药种植</td></tr>
|
||
<tr><td>大唐药业</td><td><a href="https://valuefrontier.cn/company?scode=920433" target="_blank" class="link link-hover text-blue-400">920433</a></td><td>入选'中药'概念，民族中药特色</td><td>民族中药, 北交所</td></tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
|
||
</section>
|
||
|
||
</div>
|
||
|
||
<script>
|
||
var chartDom = document.getElementById('industry-chart');
|
||
var myChart = echarts.init(chartDom);
|
||
var option;
|
||
|
||
option = {
|
||
backgroundColor: 'transparent',
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
axisPointer: {
|
||
type: 'cross',
|
||
crossStyle: {
|
||
color: '#999'
|
||
}
|
||
}
|
||
},
|
||
legend: {
|
||
data: ['总营收(亿元)', '净利润(亿元)', '十年营收CAGR'],
|
||
textStyle: {
|
||
color: '#ccc'
|
||
}
|
||
},
|
||
grid: {
|
||
left: '3%',
|
||
right: '4%',
|
||
bottom: '3%',
|
||
containLabel: true
|
||
},
|
||
xAxis: [
|
||
{
|
||
type: 'category',
|
||
data: ['2023年', '2024H1'],
|
||
axisPointer: {
|
||
type: 'shadow'
|
||
},
|
||
axisLine: {
|
||
lineStyle: {
|
||
color: 'rgba(255, 255, 255, 0.3)'
|
||
}
|
||
}
|
||
}
|
||
],
|
||
yAxis: [
|
||
{
|
||
type: 'value',
|
||
name: '金额(亿元)',
|
||
min: 0,
|
||
max: 4000,
|
||
interval: 1000,
|
||
axisLabel: {
|
||
formatter: '{value}'
|
||
},
|
||
axisLine: {
|
||
lineStyle: {
|
||
color: 'rgba(255, 255, 255, 0.3)'
|
||
}
|
||
},
|
||
splitLine: {
|
||
lineStyle: {
|
||
color: 'rgba(255, 255, 255, 0.1)'
|
||
}
|
||
}
|
||
},
|
||
{
|
||
type: 'value',
|
||
name: '增长率(%)',
|
||
min: 0,
|
||
max: 10,
|
||
interval: 2,
|
||
axisLabel: {
|
||
formatter: '{value} %'
|
||
},
|
||
axisLine: {
|
||
lineStyle: {
|
||
color: 'rgba(255, 255, 255, 0.3)'
|
||
}
|
||
},
|
||
splitLine: { show: false }
|
||
}
|
||
],
|
||
series: [
|
||
{
|
||
name: '总营收(亿元)',
|
||
type: 'bar',
|
||
tooltip: {
|
||
valueFormatter: function (value) {
|
||
return value + ' 亿元';
|
||
}
|
||
},
|
||
itemStyle: {
|
||
color: new echarts.graphic.LinearGradient(0, 0, 0, 1, [
|
||
{ offset: 0, color: '#8360c3' },
|
||
{ offset: 1, color: '#2ebf91' }
|
||
])
|
||
},
|
||
data: [3721, 1894.34]
|
||
},
|
||
{
|
||
name: '净利润(亿元)',
|
||
type: 'bar',
|
||
tooltip: {
|
||
valueFormatter: function (value) {
|
||
return value + ' 亿元';
|
||
}
|
||
},
|
||
itemStyle: {
|
||
color: new echarts.graphic.LinearGradient(0, 0, 0, 1, [
|
||
{ offset: 0, color: '#3b82f6' },
|
||
{ offset: 1, color: '#60a5fa' }
|
||
])
|
||
},
|
||
data: [null, 230.06]
|
||
},
|
||
{
|
||
name: '十年营收CAGR',
|
||
type: 'line',
|
||
yAxisIndex: 1,
|
||
tooltip: {
|
||
valueFormatter: function (value) {
|
||
return value + ' %';
|
||
}
|
||
},
|
||
itemStyle: {
|
||
color: '#facc15'
|
||
},
|
||
lineStyle: {
|
||
width: 3,
|
||
shadowColor: 'rgba(250, 204, 21, 0.5)',
|
||
shadowBlur: 10
|
||
},
|
||
data: [9.6, null]
|
||
}
|
||
],
|
||
textStyle: {
|
||
color: '#E0E0E0'
|
||
}
|
||
};
|
||
|
||
option && myChart.setOption(option);
|
||
window.addEventListener('resize', function() {
|
||
myChart.resize();
|
||
});
|
||
</script>
|
||
|
||
</body>
|
||
</html> |